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treatment can bring immediate relief and po-
tentially produce a rapid and complete reso-
lution of all lesions. Conversely, failure to 
diagnose and treat correctly can prolong the 
patient’s suffering over considerable periods 
of time. Direct microscopy and culture [2] 
are rapid, sensitive and specific noninvasive 
diagnostic tests that can reveal at an afford-
able cost (€ 23.30) whether or not fungal in-
fection is present.
The most frequent systemic antifungals used 
for treatment of superficial mycoses are gris-
eofulvin (the “gold standard” in tinea capi-
tis), azoles (itraconazole and fluconazole) 
and allylamines. Topical therapy is used in 
the limited forms of the infection and when-
ever hair or nails are not involved, and as 
an adjuvant to systemic therapy. Polyenes, 
IntroductIon
Superficial mycoses (dermatophytosis, can-
didiasis and infections by non-dermatophyte 
molds) can affect the scalp, glabrous skin, 
nails and skin folds and are estimated to af-
fect more than 20-25% of the world’s popu-
lation, with a consistent increase over time 
[1]. They often present with characteristic 
lesions, but can be difficult to diagnose and 
may be mistaken for other cutaneous disor-
ders. Indeed their clinical manifestation can 
vary according to several factors, including 
the site of infection, immunological status of 
the host and the fungal species.
Thus, laboratory investigation to identify the 
fungus responsible for the infection is essen-
tial for correct diagnosis and management 
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AbstrAct
Superficial mycoses are estimated to affect more than 20-25% of the world’s population with a consistent increase over the 
years. Most patients referred to our clinic for suspected dermatomycoses have already been treated with pharmacotherapy, 
without a previous mycological examination and many show changes in the clinical manifestations. Indeed, some medica-
tions, such as steroids, antiviral, antibiotics and antihistamines are not able to erase a fungal infection, but also they can 
cause atypical clinical manifestations.
The consequences of inappropriate treatment include delayed diagnosis, prolonged healing time, and additional costs. The 
aims of this study were (1) to evaluate the incidence of increased costs attributable to inappropriate therapy sustained by 
the National Health Service and patients and (2) to highlight the importance of mycological evaluation before starting treat-
ment, in order to improve diagnostic accuracy. An observational retrospective and prospective study was performed from 
September 2013 to February 2014, in 765 patients referred to our center (University Hospital “ Federico II”) in Naples, 
Italy, for suspected mycological infection. The following treatments (alone or in combination) were defined as inappropri-
ate: (1) cortisone in a patient with at least one positive site; (2) antifungals in (a) patients with all negative sites or (b) inef-
fective antifungal treatment (in terms of drug chosen, dose or duration) in those with all positive sites; or (3) antibiotics; 
(4) antivirals or (5) antihistamines, in patients with ≥ 1 positive site. Five hundred and fifty patients were using medications 
before the assessment visit. The total amount of avoidable costs related to inappropriate previous treatments was € 121,417, 
representing 74% of the total treatment costs. 253/550 patients received drugs also after the visit. For these patients, the 
cost of treatment prescribed after mycological testing was € 42,952, with a decrease with respect to the total consumption 
of drugs at the time of access to the Mycology Laboratory of € 34,781.
Thus, our cost analysis shows that it is important to obtain a reduction of costs for pathologies that need to be confirmed 
by examinations before starting treatment. 
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tive mycological testing, prescribed therapies 
were recorded. For each patient and each 
treatment taken over time, drug consumption 
was recorded based on estimates of the dose 
according to the site of infection reported in a 
previous study [7].
Dosages were calculated based on the esti-
mated number of affected locations, using an 
algorithm that correlates the amount of drug 
used (for the site) and the amount of drug 
contained in the package (tablets, ointments, 
sprays, solutions, vials) to derive the overall 
consumption of the active drug principle. All 
active principles reported were grouped ac-
cording to the ATC classification. For each 
active principle the corresponding marketed 
formulation was identified and the corre-
sponding pack price retrieved [8]. The price 
of treatment was calculated based on the av-
erage price per unit and usage (dosage and 
duration) for each drug therapy that was used 
for the treatment of specific locations of my-
coses.
Average and total cost for the previous treat-
ments (before-visit) and total and average 
cost for the treatment of patients after the 
positive mycological test (post-visit) were 
calculated.
Based on the outcome of the mycological 
investigation, we identified patients who had 
received inappropriate drug therapies prior to 
the visit. The following treatments, alone or 
in combination, were considered inappropri-
ate:
1. cortisone prescribed to a patient with at 
least one positive site;
2. antifungals
 - in patients with all negative sites;
 - ineffective antifungal therapy in pa-
tients with all positives sites (inappro-
priate drug, dose or duration);
3. antibiotics in patients with at least one 
positive site;
4. antivirals in patients with at least one pos-
itive site; and
5. antihistamines in patients with at least 
one positive site.
Thus, two categories were identified:
1. patients not actually affected by mycosis 
but treated with antimycotic agents; and
2. patients with confirmed mycosis who 
were given inappropriate treatment, in 
terms of the active agent, the dosage or 
the duration.
The total cost of inappropriate prescriptions 
was calculated as a proportion of the total 
cost sustained before the hospital visit for 
these patients. For patients who received a 
drug therapy prior to the visit and were pre-
scribed new therapies after a positive myco-
logical test, costs were also calculated for the 
azoles, allylamines, hydroxypyridone such 
as ciclopiroxolamine, and morpholine de-
rivatives in cream, solution, nail lacquer, and 
powder formulations are the most important 
topical agents used [3].
At the Mycology Laboratory of the Univer-
sity of Naples “Federico II”, we see each year 
approximately 1,700 patients with suspected 
mycological infection. These patients are re-
ferred to our center by dermatologists and 
general practitioners (GP)s, for confirmation 
of the diagnosis by mycological examination. 
Most patients have already received pharma-
cological treatment without previous myco-
logical testing. In many cases these patients 
have shown changes in the clinical manifes-
tations. Some medications such as steroids, 
antivirals, antibiotics and antihistamines, that 
are not able to eradicate fungal infections, 
can also cause atypical clinical manifesta-
tions [4]. Indeed, the most important factor 
influencing the clinical appearance seems to 
be prolonged use of steroids, especially topi-
cal steroids [5,6].
As a result, patients may face delayed diag-
nosis and prolonged healing time, as well 
as economic impact. Where costs are reim-
bursed, this also has an impact on the Nation-
al Health System.
objectIves of the study
The aims of this study were:
1. to evaluate the incidence of costs attribut-
able to inappropriate therapy sustained by 
the National Health Service and patients; 
and
2. to highlight the importance of mycologi-
cal investigations before starting treat-
ment, in order to improve diagnostic ac-
curacy.
Methods
An observational retrospective and prospec-
tive study was performed from September 
2013 to February 2014. We enrolled all pa-
tients referred to the Mycology Laboratory 
of the University Hospital of Naples “Fed-
erico II” – Department of Clinical Medicine 
and Surgery for suspected mycological in-
fection. Using a purpose-built database, we 
retrospectively checked previous pharmaco-
logical treatments taken by each patient. Ac-
tive ingredient, dosage form, and prescribed 
dosage and duration were recorded for each 
treatment. At enrolment (visit) a mycologi-
cal investigation was performed and results 
were recorded, classified by site (single site/
multiple locations). For the subset of patients 
who received new drug therapies after posi-
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Treatment prior to clinic visit
As already mentioned, drug treatments prior 
to the visit were recorded on the basis of the 
information provided by the patients them-
selves. The total cost of drugs was estimated 
at € 163,536, corresponding to an average of 
€ 297 per patient. The vast majority of drugs 
(85.6%) were classified as NHS reimburse-
ment Class C (paid for by the patient) and 
ATC Class D (dermatological drugs; 90.7%) 
(Table I).
Antifungals (Classes D01A+D01B+J02AC 
of the ATC classification) accounted for more 
than half of the drugs used by the patients be-
fore the specialist visit and cortisone (Classes 
ATC D07 and H02AB) for almost one-third. 
Antibiotics, antivirals and antihistamines 
were infrequently used, while remaining 
drugs were represented almost exclusively 
by psoriasis treatments (ATC D05AX). Drug 
consumption was very low for young patients 
and increased with age (Kruskall-Wallis test; 
p = 0.0065 for ≤ 18, 19-64 vs ≤ 65 years); 
there was no difference in drug usage be-
tween male and female patients (Mann-Whit-
ney test; p = 0.87). Multiple sites of disease 
(body and skin folds; nail and body; nail 
and body with skin folds) were associated 
with high average consumption of drugs, al-
though the site that most frequently required 
multiple drugs was nails (23.1%) (Kruskall-
Wallis p < 0.0001 considering all sites and 
their combinations). Drugs were mostly used 
by patients referred by GPs and by patients 
with psoriasis (not statistically significant). 
It is notable that 4 drugs/drug combinations: 
amorolfine (12.64%); diflucortone/isocon-
azole (10.68%); calcipotriol/betamethasone 
(10.50%) and gentamicin/betamethasone 
(10.17%) accounted for almost half of the 
consumption of drugs in the “before-visit” 
period.
Two hundred and eighty six of the 550 pa-
tients with previous treatments (52%) tested 
negative for fungal infection in single or 
multiple locations, while 264 (48%) test-
aTC Description
Cost
Class a Class C Total
€ % € % € %
D Dermatological drugs 9,565.08 39.1 138,786.5 99.8 148,351.62 90.7
H Systemic hormonal preparations 666.86 2.7 0 0.0 666.86 0.4
J Anti-infective drugs for systemic use 13,104.37 53.6 0 0.0 13,104.37 8.0
N Nervous system drugs 0 0.0 138.75 0.1 138.75 0.1
R Respiratory system drugs 1,095.57 4.5 178.65 0.1 1,274.22 0.8
Total 24,431.88 100.0 139,103.94 100.0 163,535.82 100.0
Table i. Drug cost distribution according to previous consumption classified by ATC group
treatment after the evaluation (post-visit). 
Additionally, the study aimed to estimate the 
cost borne by the patients and by the Region-
al Health Service for visits and examinations.
To estimate costs for visits, we distinguished 
patients referred by a specialist from those 
referred by GPs. For the first group we es-
timated that approximately 60% of patients 
had a private visit (internal data from the 
center), while for the remaining patients an 
outpatient visit and a GP visit were accounted 
for. The cost to the Regional Health Service 
for a GP visit was estimated at € 15 [9], while 
the reimbursement for a specialist dermato-
logic visits was estimated at € 20.66 [10]. 
The mean cost for a private dermatologic 
visit was estimated to be € 70 [11]. The cost 
for a mycological examination was estimated 
as € 23.34 [10] for a patient without exemp-
tion and € 13.30 for a patient with exemption 
code E05 [10], while for a patient with total 




A total of 765 patients were enrolled in the 
period September 2013-February 2014. Of 
these, 550 (71.9%) reported receiving pre-
vious therapies. Their average age was 46.6 
years (45.3 years for male; 47.6 years for 
female patients); 91.6% of patients were re-
ferred by a specialist and 8.4% by GPs; 4.7% 
of patients had diabetes and 24.7% had pso-
riasis as a concomitant disease. The body 
sites affected varied considerably, with nails 
and body infections predominating, but many 
patients had multiple affected sites. The scalp 
was most commonly affected in young pa-
tients (mean age was 14.4 years), while nail 
infections (with or without involving other 
sites), more commonly affected older pa-
tients. Mean age was significantly lower for 
affected scalp than affected nails (Wilcoxon 
test; p < 0.0001).
© SEEd All rights reserved42 Farmeconomia. Health economics and therapeutic pathways 2015; 16(2)
Cost analysis of inappropriate treatments for suspected dermatomycoses
ed positive in at least one locations; 238 
(43.3%) tested positive in single or multiple 
locations.
Of the 550 patients who had received drug 
therapy before the visit, 253 were found to 
be positive for mycosis and were prescribed 
drug therapies after the visit. The remain-
ing 297 patients were referred to other di-
agnostic-therapeutic pathways. For the 253 
patients taking medications both before and 
after the visit to the specialist center, the total 
cost of drugs before the visit was estimated to 
be € 77,733.42 corresponding to € 307.25 per 
capita, with female patients accounting for a 
higher proportion of cases (64.03%) and total 
(72.4%) and average (+47.39% with respect 
of males) consumption (Mann-Whitney test; 
p = 0.59; not statistically significant).
Consumption of drugs after the visit
For the 253 patients prescribed drugs after 
mycological testing, the cost of the prescribed 
drugs amounted to a total of € 42,920.89 (Ta-
ble II), corresponding to € 169.65 per capita.
The reported cost for treatments after the 
visit was significantly lower in younger 
than in older patients (Kruskall-Wallis test; 
p < 0.0001 for ≤ 18, 19-64 versus ≥ 65 years).
Infections involving nails were associated 
with the highest treatment costs (Kruskall-
Wallis test; p < 0.0001). No significantly sta-
tistically differences in costs were reported in 
classes based on immunodeficiency or con-
comitant diseases. For all patients, the costs 
for previous treatment (from the onset of 
the disease to enrolment) were significantly 
higher than costs for the post-visit period 
(Wilcoxon paired test; p = 0.028).
Cost for inappropriate treatments
The total cost of the therapies used by the 
patients before the assessment visit was 
€ 163,536, with inappropriate treatments ac-
counting for € 121,417 (Table III).
For the 253 patients who were prescribed 
new treatments after completion of myco-
logical testing, the total amount of avoidable 
costs for inappropriate previous treatments 
was € 65,30827, while the cost of appropriate 
treatment prescribed after the visit and my-
cological testing was € 42,921. For patients 
who tested negative for cutaneous mycoses, 
the cost of treatment post-examination was 
not calculated, as they were referred for fur-
ther diagnosis, but the total cost of their pre-
vious antifungal therapy was approximately 
€ 51,182 (mean cost € 178) (statistical data to 
be reckoned with).
Drug Formulation aTC MP reimbursement class
Cost
€ %
Amorolfine 5% Nail lacquer D01AE16 40.70 C 366.30 0.85
Ciclopirox olamine Cream D01AE14 7.62 C 13,896.36 32.38
Ciclopirox olamine Powder D01AE14 8.65 C 3,044.80 7.09
Ciclopirox olamine Emulsion D01AE14 8.95 C 125.30 0.29
Ciclopirox olamine Nail lacquer D01AE14 27.00 C 3,753.00 8.74
Fluconazole 100 mg Tablet J02AC01 28.46 A 18,555.92 43.23
Griseofulvin 125 mg Tablet D01BA00 1.96 A 86.24 0.20
Griseofulvin 500 mg Tablet D01BA01 3.15 A 667.80 1.56
Itraconazole 100 mg Tablet J02AC02 8.29 A 1,989.60 4.64
Miconazole Powder D01AC02 9.03 C 216.72 0.50
Terbinafine 250 mg Tablet D01BA02 14.59 A 218.85 0.51
Total     42,920.89 100
Table ii. Drug cost distribution after mycological testing according to ATC category




Antifungals in patients with 
all negative sites
D01A+D01B+J02AC 51,182.54 42.15
Antifungals in patients 
with all positive sites 
(inappropriate drug, dose 
or duration)
D01A+D01B+J02AC 38,057.13 34.34
Cortisone in patients with 
≥ 1positive site
D07+H02AB 28,338.25 23.44
Antibiotics in patients with 
≥ 1 positive site
D03BA+D06A+J01 2,968.01 2.44
Antivirals in patients with 
≥ 1 positive site
D06B+J05 27.80 0.02




Table iii. Inappropriate costs for drugs according to ATC categories
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can be achieved by first conducting myco-
logical examinations.
In our study, 550 (71.9%) of 765 enrolled 
patients were using medications before the 
assessment visit. The total cost of these 
therapies was € 163,536, with inappropriate 
treatments accounting for € 121,417. There-
fore, our findings indicate that 74% of the 
total cost borne by the NHS and the patients 
related to inappropriate treatments before the 
visit to our clinic could have been avoided if 
all prescriptions were optimal.
For the 253 patients who were prescribed new 
treatments after completion of mycological 
testing, the total amount of avoidable costs 
for inappropriate previous treatments repre-
sented 84% (€ 65,30827 out of € 77,733.42) 
of the total cost borne by the NHS and the 
patients, while the cost of appropriate treat-
ment prescribed after the visit and mycologi-
cal testing was € 42,921, with a decrease with 
respect to the total consumption of drugs at 
the time of access to the Mycology Labora-
tory of € 34,813.
The vast majority of drugs consumed are 
classified as NHS reimbursement Class C 
(86%) and more than half of the drugs used 
by the patients before the specialist visit were 
antifungals (Classes D01A+D01B+J02AC of 
the ATC classification), in particular amorol-
fine nail lacquer, and almost one-third were 
topical cortisone (alone or in combination). 
These data highlight the high incidence of 
self-medication by the patient with drugs 
available at the pharmacy without prescrip-
tion.
Almost all of our patients who had already 
undergone therapy, were referred by a spe-
cialist dermatologist after failure of previous 
therapies (92%). Thus, it would be useful to 
encourage specialists to send patients for my-
cological testing in the first instance, rather 
than trying therapies that could prove inap-
propriate.
conclusIons
This analysis illustrates the need to reduce 
healthcare costs arising from inappropriate 
treatments. In the setting of suspected my-
cological infections, testing is inexpensive, 
non-invasive, and has a short waiting time 
(maximum 15 days). It is important to note 
that our results are from a single region of 
Italy (Campania) and generalizability to the 
entire Italian population may be limited.
Cost for visits and testing
Considering all of the 765 patients analyzed, 
the total cost borne by the regional health-
care service for the specialist or GP public 
visits was € 9,995.36, while the cost sus-
tained by the patients for private visits was 
€ 29,431.08. Ninety-five percent of patients 
were totally exempt, so the total cost borne 
by the regional healthcare service for the my-
cological visit and testing was € 16,933.28. 
The remaining patients (5%), to whom co-
payment applied, paid a total of € 891.23.
dIscussIon
A treatment is considered appropriate when 
there is clear evidence to support its use for 
the given indication, it is well tolerated and 
has a favorable cost-effectiveness profile 
[13]. Inappropriate prescribing also includes 
the use of drugs with incorrect duration, drug 
interactions and duplications [14]. Avoiding 
inappropriate treatments is very important for 
cost-containment programs within health ser-
vices.
The mycology unit of our institution has had 
a service agreement with the national health 
system for approximately forty years. Re-
cently we have seen an increased number of 
patients presenting with suspected mycoses 
that have already been treated with protracted 
systemic and/or topical drug therapy without 
laboratory confirmation of infection. Too of-
ten a diagnosis of skin mycosis (scalp, body, 
folds, and nails) is made based on clinical 
observation alone and this can lead to misdi-
agnosis and inappropriate treatment. As well 
as cost implications, inappropriate treatment 
can mask the fungal infection [15-19]. More-
over, systemic antifungal therapy can have 
serious consequences when prescribed to 
certain patient groups, e.g. those with comor-
bidities or who are immunocompromised or 
elderly, who may have impaired metabolism 
of these drugs [20].
Thus, it is important to confirm the diagnosis 
with a simple microscopic examination and 
culture. This can hasten healing and improve 
the quality of life of the patient, while avoid-
ing inappropriate costs to the national health 
system and patient [21]. Many studies have 
explored the potential to avoid unnecessary 
costs resulting from inappropriate therapy 
[22-24], but this is the first that focuses on 
mycotic skin infections and cost savings that 
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